English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

ObjectiveTo investigate the clinical and pathological characteristics of arsenic-related bladder cancer.MethodsFrom 2008 through 2011, data on 7699 patients with bladder cancer were extracted from the Taiwan Cancer Registry Database. A diagnosis of bladder cancer (International Statistical Classification of Diseases and Related Health Problems, 9th Revision: 188) was confirmed in all patients. Using birth residency codes, patients were divided into three groups: the core zone (CZ; an arsenic endemic area with well water arsenic levels of 350–1100 ng/mL); zone 1 (Z1; an area with well water arsenic levels of≥350 ng/mL but not a blackfoot disease-endemic area); and zone 2 (Z2; an area with well water arsenic levels of<350 ng/mL). Clinicopathological characteristics and survival outcomes were compared between the three groups.ResultsIn this cohort, 119 (1.5%), 1145 (14.9%), and 6435 (83.6%) patients were born in the CZ, Z1, and Z2, respectively. A higher proportion of female patients (35.3%, 31.4%, and 27.5%; p = 0.014) and lower smoking rates (29%, 34.8%, and 35.9%; p = 0.694) were noted in the CZ compared with Z1 and Z2. CZ patients had more high-grade differentiated (80.9%, 69.9%, and 63.0%; p < 0.001) and high clinical stage (stages II–IV, 52.8%, 38.1%, and 31.8%; p < 0.001) tumors compared with Z1 and Z2 patients. Radical cystectomy was infrequently performed for clinical stage II (19.6%) and stage III (25.2%) bladder cancer patients. CZ patients had significantly shorter overall and cancer-specific survival durations compared with Z1 and Z2 patients. Older age, female sex, higher tumor grade or stage, and higher arsenic levels were associated with both poorer overall and cancer-specific survival in a multivariate analysis with a Cox proportional model.ConclusionIn Taiwan, patients with arsenic-related bladder cancer may have poorer tumor characteristics and decreased overall and cancer-specific survival rates

Characteristics of arsenic-related bladder cancer: A study from Nationwide Cancer Registry Database in Taiwan